Develop new pharmaceuticals against your target structures, tune the properties of pharmaceuticals towards your needs, or identify new pharmaceutical targets.
Discrimination between agonistic and antagonistic behaviour of pharmaceutical relevant substances.
Classical assay design only allows to discriminate between binding or non-binding of pharmaceutically relevant substances to their targets. Although it might be possible to discriminate between agonistic and antagonistic behaviour via enthalpy and entropy, this is not done easily and sometimes simply impossible. We present an alternative way how this can be achieved much easier via an intelligent assay design on the example of the Estrogen Receptor alpha and two model substances.
HTS epitope mapping for antibody characterisation.
Therapeutic antibodies represent a relatively new group among the pharmaceutically interesting substances. But as all substances they need to be carefully characterised. We show the possibility for HTS epitope mapping on the example of a well, characterised antibody system.Download PDF
Identification of (cancer) biomarkers and potential new drugs via HTS screening of protein-peptide interactions.
Peptides can serve as pharmacological active substances if synthesised accordingly. Usually a large pool of peptides has to be screened and the selected hits have to be tuned in terms of sequence to optimise the affinity of the peptides to their target. We show the possibility to select and characterise different peptides interacting with the Grb2 protein, which plays a crucial role in cancer.
Investigation of receptor / small molecule interaction.
The interaction of the Estrogen Receptor alpha and a pharmaceutically active substance was monitored and the biomolecular interaction was characterised. Kinetic rate constants as well as the affinity of the small molecule towards the receptor was obtained.